TP53 and ovarian cancer: While genetic abnormalities of the p53 protein have been observed in most advanced ovarian cancer patients, the p53 vaccine did not provide enough improvement in subsequent chemosensitivity or progression-free survival (Leffers et al. 2009; Rahma et al. 2012).